Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Fallopian Tube Neoplasms 4Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leiomyosarcoma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × cediranib × Clear all
NCT02974621 2025-08-03

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡